SGLT-2 I is a great help in the treatment of heart failure

Jung Young-jin, head of the cardiovascular center at Yongin Myeongju Hospital

Improvement of heart failure symptoms such as difficulty breathing

Expected expansion of other cardiovascular diseases such as myocardial infarction

SGLT-2 inhibitors developed for the purpose of treating diabetes are speeding up the expansion into the area due to heart failure.

 

The use of SGLT-2 inhibitors targeting heart failure is expanding not only in university hospitals but also in the local area.

 

This trend has been expanding since the revision of the domestic heart failure guidelines last year.

 

Although benefits are still limited, expectations for the drug are said to be very high at the front-line prescription site.

 

Jung Young-jin (37), head of the cardiovascular center at Yongin Myeongju Hospital, said, "SGLT-2 inhibitors are very helpful in treating heart failure.

 

He said, "The effect of improving major symptoms of heart failure, including difficulty breathing, is visible," adding, "Personally, we are more actively prescribing SGLT-2 inhibitors to heart failure patients than in the past." ◆SGLT-2 Inhibitor, Improvement of Heart Failure Symptoms Visibly The Korean Heart Failure Association revised the guidelines for heart failure treatment in July last year.

 

The revised guidelines recommended SGLT-2 inhibitors as the main treatment for heart failure treatment regardless of the presence or absence of diabetes.

 

It was used limitedly only to reduce heart rate and mildness during heart failure, but the revision of the guidelines added an area to preserve heart rate.

 

The pharmaceutical industry predicts that SGLT-2 inhibitors will become the basic treatment for heart failure.

 

SGLT-2 inhibitors have previously been known to be diabetes treatments that benefit cardiovascular diseases.

 

Still, their status has risen significantly as the results of solo clinical trials on heart failure patients were announced in 2019.

 

Expectations for this drug are high even at the front-line prescription site.

 

Jung Young-jin, head of the cardiovascular center at Yongin Myeongju Hospital, said, "It is prescribed a lot to patients with heart failure who do not have diabetes," adding, "Improvement of major heart failure symptoms, including difficulty breathing, is visible." Jung, head of the center, said, "It was often used in heart failure patients in the past, but I have been using it more actively since a paper was published last year that it is effective in heart failure patients whose heart function is preserved." He added, "We are seeking consent from patients and prescribing them because the salary has not yet been applied." The pharmaceutical industry also predicts that SGLT-2 inhibitors will be able to further expand their areas in the future.

 

SGLT-2 inhibitors are mechanisms that selectively inhibit SGLT-2 transporters involved in the reabsorption of glucose.

 

Through this, blood sugar is controlled by blocking the reabsorption of glucose discharged into the urine into the bloodstream.

 

In this process, SGLT-2 inhibitors also inhibit the secretion of inflammatory cytokines, which has the effect of treating heart failure.

 

Considering this mechanism alone, it is estimated to be effective not only for heart failure but also for cardiovascular disease as a whole.

 

This means that SGLT-2 inhibitors can be used to treat heart failure and other cardiovascular diseases such as myocardial infarction.

 

Already in the United States and Europe, a paper has been published on the effect of SGLT-2 inhibitors on the treatment of myocardial infarction.

 

AstraZeneca and Beringer Ingelheim, which have major drugs, are undergoing phase 3 clinical trials for myocardial infarction.

 

The two clinical results are scheduled to be released this year.

 

He also agreed with the possibility.

 

Since the most common cause of heart failure is ischemic heart failure, I think it will be effective in other cardiovascular areas, said he, head of the center.

 

"There is a possibility in terms of the mechanism."